{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.1444.3.176",
  "meta" : {
    "versionId" : "6",
    "lastUpdated" : "2023-06-23T16:14:24.000-04:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "American Society of Clinical Oncology Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2022-12-15"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2023-06-23"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.176",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.1444.3.176"
    }
  ],
  "version" : "20210319",
  "name" : "ImmunotherapyAdministration",
  "title" : "Immunotherapy Administration",
  "status" : "active",
  "experimental" : false,
  "date" : "2021-03-19T01:00:22-04:00",
  "publisher" : "American Society of Clinical Oncology Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: The purpose of this value set is to represent concepts for the procedure of immunotherapy administration.),(Data Element Scope: This value set may use a model element related to Procedure.),(Inclusion Criteria: Includes concepts that represent a procedure for immunotherapy administration.),(Exclusion Criteria: Excludes CAR T-cell and TIL therapies.)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "concept" : [
          {
            "code" : "XW03351",
            "display" : "Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1"
          },
          {
            "code" : "XW033C3",
            "display" : "Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3"
          },
          {
            "code" : "XW04351",
            "display" : "Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1"
          },
          {
            "code" : "XW043C3",
            "display" : "Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3"
          },
          {
            "code" : "XW23346",
            "display" : "Transfusion of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6"
          },
          {
            "code" : "XW23376",
            "display" : "Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6"
          },
          {
            "code" : "XW24346",
            "display" : "Transfusion of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6"
          },
          {
            "code" : "XW24376",
            "display" : "Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:92404b7e-96f3-4702-967a-9dc13357d966",
    "timestamp" : "2023-11-26T19:55:08-05:00",
    "total" : 0
  }
}
